Hepatic arterial infusion (HAI) of oxaliplatin with either LV5FU2 or FOLFIRI in patients (pts) with refractory metastatic colorectal cancer (mCRC).
A. Rahal
No relevant relationships to disclose
D. Malka
Consultant or Advisory Role - Roche
Honoraria - Merck Serono; Sanofi
Other Remuneration - Roche
D. Goéré
No relevant relationships to disclose
V. Boige
Consultant or Advisory Role - Pfizer
Honoraria - Merck Serono
Other Remuneration - Merck Serono; Roche
T. De Baere
No relevant relationships to disclose
D. Elias
No relevant relationships to disclose
F. Deschamps
No relevant relationships to disclose
C. Rahal
No relevant relationships to disclose
M. Ducreux
Honoraria - Merck Serono
Research Funding - Roche